A Phase 2 interventional study of Rapamycin cream and Pulsed dyed laser in Port Wine Stains, sponsored by AFT Pharmaceuticals, Ltd.. Not yet recruiting at 2 sites in 2 countries. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by AFT Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks. The main question it aims to answer is:
Will rapamycin cream and laser treatment show a greater improvement in appearance of port wine birthmarks, compared to treatment with placebo cream and laser?
Researchers will compare two concentrations of rapamycin cream (0.6% or 1.0%) with placebo treatment to see if appearance is improved following 12 weeks of treatment.
Participants will receive laser treatment of their port wine birthmark and then apply the rapamycin or placebo cream daily for 12 weeks. Patients will visit the clinic every 4 weeks for checkups and tests.
This is a single-centre, double-blind, randomized withdrawal design, parallel group, placebo-controlled, dose-response clinical study investigating the efficacy and safety of two concentrations of topical rapamycin cream in the treatment of port wine stain as an adjunct to pulsed dyed laser (PDL) in paediatric patients. 30 participants will be enrolled into the study.
The study hypothesis is that topical rapamycin, as an adjunct to PDL, will show a dose-dependent increase in the blanching of port wine birthmarks, compared to PDL with placebo after 12 weeks.
Eligible participants will undergo PDL treatment of their entire port wine birthmark. Patients that respond positively to PDL within 5 days will be enrolled and randomized, before the first application of the study drug. Participants will be randomly assigned to one of three possible treatments in a 1:1:1 ratio:
During this phase of the study, four clinical visits will occur, one every 4 weeks for 12 weeks. Assessment of the extent and severity of birthmark size and colour will be performed at randomization, at each clinical visit, and at follow-up using photography and percentage improvement ratings. Safety will be assessed by recording all adverse events experienced and testing blood rapamycin concentration at prior to treatment and at the last clinical visit.
Follow-up will be performed 28 days after the last cream application. An extra PDL session will be optionally provided at the follow-up appointment. If PDL treatment occurs at the follow-up visit, a further follow-up phone call will occur 7±2 days after the second PDL session to assess concomitant medications and adverse events.
AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.6% rapamycin cream applied daily
Drug: Rapamycin cream · Procedure: Pulsed dyed laser
1.0% rapamycin cream applied daily
Drug: Rapamycin cream · Procedure: Pulsed dyed laser
Placebo cream applied daily
Procedure: Pulsed dyed laser
Application of rapamycin cream to port wine birthmark
Pulsed dyed laser (PDL) treatment of port wine birthmark
Clinic Objective improvement rating at week 12
The average percentage improvement (0-100% with higher scores being a better outcome) of port wine stain appearance in the cream treated area from baseline to week 12, or at last visit if early withdrawal/discontinuation occurs, as assessed by the principal investigator during the clinic visit.
Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application
Subjective improvement rating (all timepoints)
Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) of port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment.
Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application
Clinic Objective improvement rating (all timepoints)
Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) in port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment
Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application
Photographic Objective improvement rating (all timepoints)
Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, in port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment
Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application
Subjective improvement rating change at follow-up
Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area from baseline at follow-up visit
Time frame: From before laser treatment to follow-up visit (16 weeks)
Subjective improvement rating (post-treatment)
Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area between week 12 and follow-up
Time frame: 4 weeks between end of treatment and follow-up visit
Clinic Objective improvement rating change at follow-up
Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area from baseline at follow-up visit
Time frame: From before laser treatment to follow-up visit (16 weeks)
Clinic Objective improvement rating (post-treatment)
Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area between week 12 and follow-up
Time frame: 4 weeks between end of treatment and follow-up visit
Photographic Objective improvement rating change at follow-up
Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, change of cream treated area from baseline at follow-up visit
Time frame: From before laser treatment to follow-up visit (16 weeks)
Photographic Objective improvement rating (post-treatment)
Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, change of cream treated area between week 12 and follow-up
Time frame: 4 weeks between end of treatment and follow-up visit
Categorical Improvement of port wine stain
Categorical Improvement (5-point scale with higher scores being a better outcome) of port wine stain in cream treated area from baseline after 12 weeks of treatment.
Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application
Colorimetry rating (all timepoints)
Change in extent and intensity of port wine stain colour of the cream treated area from baseline at weeks 0, 4, 8, 12 and follow-up/last assessment, measured using a colorimetry system through standardized clinical photographs
Time frame: From before laser treatment to the follow-up visit (16 weeks)
Colorimetry intra-patient rating
Difference in extent and intensity of port wine stain colour between the two treatment areas (laser+cream or laser only) of each individual at each assessment (pre-laser baseline, weeks 0, 4, 8, 12 and follow-up/last assessment) using the colorimetry system
Time frame: From before laser treatment to the follow-up visit (16 weeks)
Subjective intra-patient rating
Difference in subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) of port wine stain between the treatment areas (laser+cream or laser only) of each individual at each assessment (week 0, 4, 8, 12 and follow-up/last assessment)
Time frame: From start of cream treatment to the follow-up visit (16 weeks)
Clinic Objective intra-patient rating
Difference in clinic objective (investigator) improvement rating (0-100% with higher scores being a better outcome) of port wine stain between the treatment areas (laser+cream or laser only) of each individual at each assessment (week 0, 4, 8, 12 and follow-up/last assessment)
Time frame: From start of cream treatment to the follow-up visit (16 weeks)
Photographic Objective intra-patient rating
Difference in photographic objective (committee) improvement rating (0-100% with higher scores being a better outcome) of port wine stain between the treatment areas (laser+cream or laser only) of each individual at each assessment (week 0, 4, 8, 12 and follow-up/last assessment)
Time frame: From start of cream treatment to the follow-up visit (16 weeks)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
AFT Pharmaceuticals, Ltd.